REDD1 is a determinant of the sensitivity of renal cell carcinoma cells to autophagy inhibition that can be therapeutically exploited by targeting PIM activity

Jennifer S. Carew(The University of Texas MD Anderson Cancer Center), Steffan T. Nawrocki(University of Arizona), Benjamin R. Lee(University of Arizona), Madison E. Gamble(University of Arizona), Wei Wang(Xuzhou Medical College), Maria Janina Carrera Espinoza(University of Arizona), S. Sureshkumar(University of Arizona), Claudia M. Espitia(The University of Texas System)
Cancer Letters
January 30, 2025
10.1016/j.canlet.2025.217496
Cited by 8

Related Papers

Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
|Clinical Cancer Research|2008|782
Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl–mediated drug resistance
|Blood|2007|485
Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy
|Cancer Letters|2008|426
Bortezomib Inhibits PKR-Like Endoplasmic Reticulum (ER) Kinase and Induces Apoptosis via ER Stress in Human Pancreatic Cancer Cells
|Cancer Research|2005|324
Targeting HSP90 for cancer therapy
|British Journal of Cancer|2009|320